drugset / Trial / NCT02720926
Study of TKI 258 in Combination With Xeloda and Oxaliplatin in Advanced Colorectal and Gastric Cancer
NaSingle-groupOpen-labelTreatment
Summary
Standard "3+3" dose escalation design of TKI258/XELOX in advanced gastric/gastro-oesophageal and colorectal cancer.
Timeline
- Start
- 2011-09
- Primary completion
- 2012-01
- Completion
- 2012-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dovitinib | Small molecule | 200 mg | — |
| Subject | Dovitinib | Small molecule | 300 mg | — |
| Subject | Dovitinib | Small molecule | 400 mg | — |
| Subject | Dovitinib | Small molecule | 500 mg | — |
| Background | Capecitabine | Small molecule | 2000 mg/m2 | — |
| Background | Oxaliplatin | Small molecule | 130 mg/m2 | — |